Literature DB >> 19847452

Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer.

Hervé Tixier1, Jean Fraisse, Bruno Chauffert, Françoise Mayer, Sylvain Causeret, Catherine Loustalot, Coralie Deville, Franck Bonnetain, Paul Sagot, Serge Douvier, Jean Cuisenier.   

Abstract

PURPOSE: The main aim of this study was to show the interest of pelvic posterior exenteration to obtain complete resection of the tumor in case of invasion of the rectum by contiguity in advanced-stage ovarian cancer. The secondary aim was to determine the morbidity of this surgery.
METHODS: It is a multicentric, retrospective study of a series of 41 patients, who underwent posterior pelvectomy for advanced-stage ovarian cancer, over a period of 18 years, from July 1989 to July 2007.
RESULTS: The surgery resulted in macroscopically complete resection in 19 patients (46.34%), a residual tumor <2 cm in 19 patients (46.34%) and >2 cm in 3 patients (7.32%). In 34 patients (34/41), digestive continuity with satisfactory anal sphincter function was restored immediately or in the short term. The mean delay to the start of complementary treatment was 36 days. Median overall survival was 33 months.
CONCLUSION: The main aim of surgery for ovarian peritoneal carcinomatosis is to obtain a complete resection. In the case of direct invasion of the rectum by contiguity, when there is no cleavage plane between the uterus and the rectum, pelvic posterior exenteration is an effective method to achieve this objective. Morbidity is relatively high, but acceptable given the poor prognosis of this disease, the improved survival after surgery, and improvements in post-operative quality of life and functions.

Entities:  

Mesh:

Year:  2009        PMID: 19847452     DOI: 10.1007/s00404-009-1175-0

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  Sonographic diagnosis and Endo-SPONGE assisted vacuum therapy of anastomotic leakage following posterior pelvic exenteration for ovarian cancer without using a protective stoma.

Authors:  Jens Einenkel; Babett Holler; Albrecht Hoffmeister
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

3.  Total pelvic exenteration for gynecologic malignancies.

Authors:  Elisabeth J Diver; J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Int J Surg Oncol       Date:  2012-06-10

4.  Pelvic exenteration: experience from a rural cancer center in developing world.

Authors:  Sampada B Dessai; Satheesan Balasubramanian; Vijay M Patil; Santam Chakraborty; Atanu Bhattacharjee; Syam Vikram
Journal:  Int J Surg Oncol       Date:  2015-02-08

5.  Total Parenteral Nutrition Treatment Improves the Nutrition Status of Gynecological Cancer Patients by Improving Serum Albumin Level.

Authors:  Xin Yan; Sanyuan Zhang; Junmei Jia; Jiaolin Yang; Yilai Song; Haoran Duan
Journal:  Front Med (Lausanne)       Date:  2022-01-20

6.  Surgical results of pelvic exenteration in the treatment of gynecologic cancer.

Authors:  Andrea Petruzziello; William Kondo; Sergio B Hatschback; João A Guerreiro; Flávio Panegalli Filho; Cristiano Vendrame; Murilo Luz; Reitan Ribeiro
Journal:  World J Surg Oncol       Date:  2014-09-08       Impact factor: 2.754

7.  Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.

Authors:  Gilles Houvenaeghel; Alexandre de Nonneville; Guillaume Blache; Max Buttarelli; Camille Jauffret; Djamel Mokart; Laura Sabiani
Journal:  J Gynecol Oncol       Date:  2022-02-04       Impact factor: 4.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.